Skip to main content
[Preprint]. 2022 Mar 24:2022.03.23.485509. [Version 1] doi: 10.1101/2022.03.23.485509

Figure 1. Advantages of and considerations motivating scaled PhIP-Seq.

Figure 1.

A) Schematic of vacuum-based scaled PhIP-Seq protocol, allowing for parallelized batches of 600–800 samples. B) Comparison of moderate-throughput multichannel protocol data to high-throughput vacuum-based protocol data, with axes showing normalized read percentages. Controls include a commercial polyclonal anti-GFAP antibody (left), APS1 patient A with known and validated autoantibodies RFX6, SOX10, ACPT and LCN1 (center), and APS1 patient B with the same known and validated autoantibodies as well as NKX6–3.